Cargando…

Cardiovascular Prevention in People Living With HIV: Is There a Rationale to Move Beyond Aspirin?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Silvain, Johanne, Kerneis, Mathieu, Boccara, Franck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research - Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849459/ https://www.ncbi.nlm.nih.gov/pubmed/36687268 http://dx.doi.org/10.1016/j.jacbts.2022.07.007

Ejemplares similares

Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Guedeney, Paul, et al.
Publicado: (2020)

Which people should take aspirin for primary prevention of cardiovascular disease?
por: Lozano, Roberto, et al.
Publicado: (2015)

Aspirin for Prevention of Cardiovascular Disease
por: Mendy, Vincent L., et al.
Publicado: (2017)

Aspirin for primary prevention of cardiovascular disease
por: Nansseu, Jobert Richie N., et al.
Publicado: (2015)

Aspirin for Primary Prevention of Cardiovascular Disease
por: Kim, Ji Hye, et al.
Publicado: (2019)

Cardiovascular health knowledge and preventive practices in people living with HIV in Kenya
por: Temu, Tecla M., et al.
Publicado: (2015)

The influence of healthcare financing on cardiovascular disease prevention in people living with HIV
por: Webel, Allison R., et al.
Publicado: (2020)

Cardiovascular disease and prevention among people living with HIV in South Florida
por: Pyarali, Fahim, et al.
Publicado: (2021)

Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond)
por: Crescente, Marilena, et al.
Publicado: (2018)

Aspirin overutilization for the primary prevention of cardiovascular disease
por: VanWormer, Jeffrey J, et al.
Publicado: (2014)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Aspirin for the primary prevention of cardiovascular disease in the elderly
por: O’Sullivan, Jack W
Publicado: (2019)

Use and Misuse of Aspirin in Primary Cardiovascular Prevention
por: Coccheri, Sergio
Publicado: (2017)

Aspirin in the Modern Era of Cardiovascular Disease Prevention
por: Murphy, Ella, et al.
Publicado: (2021)

Aspirin in primary prevention of cardiovascular disease in diabetes
por: Papazafiropoulou, Athanasia K., et al.
Publicado: (2021)

Nosocomial Meningitis: Moving beyond Description to Prevention
por: Kim, Hong Bin
Publicado: (2012)

An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV
por: Mystakelis, Harry A., et al.
Publicado: (2023)

Economics for people and planet—moving beyond the neoclassical paradigm
por: Brand-Correa, Lina, et al.
Publicado: (2022)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Publicado: (2010)

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
por: De Berardis, Giorgia, et al.
Publicado: (2009)

Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
por: Dai, Yuxiang, et al.
Publicado: (2012)

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events
por: Sylvester, Katelyn W, et al.
Publicado: (2013)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Aspirin use for cardiovascular disease prevention in the uninsured population
por: Liu, Nina, et al.
Publicado: (2020)

Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19
por: Diaz, Temistocles, et al.
Publicado: (2020)

Aspirin for Primary Prevention of Cardiovascular Diseases: “WALTZ” with the Evidence
por: Dimitriadis, Kyriakos, et al.
Publicado: (2022)

Livestock–Carnivore Coexistence: Moving beyond Preventive Killing
por: Chinchilla, Skarleth, et al.
Publicado: (2022)

COVID-19 vaccines safe in people living with HIV
Publicado: (2022)

The potential impact of new national guidance on primary prevention of cardiovascular disease in people living with HIV
por: Ahmed, Nadia, et al.
Publicado: (2014)

Prevention of atherosclerosis in patients living with HIV
por: De Lorenzo, Ferruccio, et al.
Publicado: (2009)

Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review
por: Bourke, L, et al.
Publicado: (2014)

Moving Beyond Self‐Reported Race in Our Understanding of Cardiovascular Medicine
por: Luo, Nancy
Publicado: (2022)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
por: Djatche, Laurence M., et al.
Publicado: (2018)

Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease
por: Chen, Yinong, et al.
Publicado: (2021)

Challenging the “Divinity” of Aspirin Monotherapy for Secondary Prevention of Cardiovascular Disease
por: Spartalis, Michael, et al.
Publicado: (2023)

Moving beyond MTBE.
por: Tenenbaum, D J
Publicado: (2000)

Moving beyond COVID
por: Tandon, Rajiv
Publicado: (2022)

Moving beyond Titers
por: Brooks, Benjamin D., et al.
Publicado: (2022)

Moving beyond MARCO
por: Rosa, Nicholas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8s1te1e0mvc4950gfbvtufaan0